Table 1 Characteristics of the included guidelines.
Guideline identifier, year released | Guideline developer and country | Disease or condition | Guideline title |
|---|---|---|---|
Cardiovascular disease and related condition | |||
NCEP, 2002 | National Heart, Lung, and Blood Institute, US | Hypercholesterolemia and coronary heart disease | National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) |
NICE1, 2006 [15] | National Institute for Health and Clinical Excellence, UK | Cardiovascular disease | Statins for the Prevention of Cardiovascular Events |
AHA1, 2006 [16] | American Heart Association and American Stroke Association, US | Ischemic stroke | Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council |
AHA2, 2007 [17] | American Heart Association, US | Cardiovascular disease | Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update |
MSC1, 2008 [18] | Medical Services Commission, British Columbia, Canada | Cardiovascular disease | Cardiovascular Disease - Primary Prevention |
NICE2, 2008 [19] | National Collaborating Centre for Primary Care, UK | Cardiovascular disease | Lipid Modification. Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease |
ACCP, 2008 [20] | American College of Chest Physicians, US | Coronary artery disease | The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) |
MSC2, 2008 [21] | Medical Services Commission, British Columbia, Canada | Hypertension | Hypertension - Detection, Diagnosis and Management |
USPSTF, 2009 [22] | U.S. Preventive Services Task Force, US | Cardiovascular disease | Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation Statement |
UMHS1, 2009 [23] | University of Michigan Health System, US | Coronary heart disease and stroke | Screening and Management of Lipids |
ICSI, 2009 [24] | Institute for Clinical Systems Improvement, US | dyslipidemia and coronary heart disease | Lipid Management in Adults |
MQIC, 2009 [25] | Michigan Quality Improvement Consortium, US | Hypercholesterolemia | Screening and Management of Hypercholesterolemia |
Cardiovascular disease and type 2 diabetes | |||
ES, 2008 [26] | The Endocrine Society, US | Cardiovascular disease and Type 2 diabetes | Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline |
Type 2 diabetes | |||
NICE3, 2008 [27] | National Clinical Guideline Centre for Acute and Chronic Conditions, UK | Type 2 diabetes | Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (update) |
MSC3, 2010 [28] | Medical Services Commission, British Columbia, Canada | Type 2 diabetes | Diabetes Care |
ADA, 2011 [29] | American Diabetes Association, US | Type 2 diabetes | Standards of Medical Care in Diabetes - 2011 |
Breast cancer | |||
UMHS2, 2007 [30] | University of Michigan Health System, US | Breast cancer | Common Breast Problems |
NSGC, 2007 [31] | National Society of Genetic Counselors, US | Breast cancer and ovarian cancer | Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: Recommendations of the National Society of Genetic Counselors |
ASCO, 2009 [32] | American Society of Clinical Oncology, US | Breast cancer | American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction |
NICE4, 2009 [33] | National Collaborating Centre for Cancer, UK | Breast cancer | Early and Locally Advanced Breast Cancer. Diagnosis and Treatment |